Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Licenses Leukemia Marker to Quest Diagnostics

NEW YORK (GenomeWeb News) – Trovagene today said it has licensed to Quest Diagnostics non-exclusive rights to incorporate the nucleophosmin protein (NPM1) into its research and testing services for acute myelogenous leukemia.

The San Diego-based molecular diagnostics firm holds the exclusive worldwide rights to an issued US patent, as well as patent applications in the US and elsewhere, covering NPM. It has licensed non-exclusive rights to the marker to several diagnostic and lab testing firms.

Under the agreement with Quest, Trovagene will receive upfront fees and royalty payments on an annual basis. Additional terms of the agreement were not disclosed.

"Physicians need accurate tools to assess prognosis, select therapies, and evaluate for bone marrow transplant," Trovagene Chief Technology Officer Charlie Rodi said in a statement. "Use of this marker can help physicians more effectively treat patients with AML."

Trovagene noted that many AMl patients have mutations in the NPM1 gene and testing for NPM1 mutations has been recommended by the National Comprehensive Cancer Network.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.